Secondary analysis of RTOG 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma with chemotherapy and hyperfractionated radiotherapy

297 Secondary Analysis of RTOG 9310: An Intergroup Phase II Combined Modality Treatment of Primary Central Nervous System Lymphoma with Chemotherapy and Hyperfractionated Radiotherapy B.J. Fisher, W. Sieferheld, C. Schultz, L. DeAngelis, D. Nelson, S.C. Schold, W. Curran Radiation Oncology, London Regional Cancer Centre, University of Western Ontario, London, ON, Canada, Statistical Unit, RTOG Headquarters, Philadephia, PA, Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, Neurology, Memorial-Sloan Kettering, New York, NY, Radiation Oncology, Mayo Clinic, Rochester, MN, Neurology, Duke University Medical Center, Durham, NC, Radiation Oncology, Thomas Jefferson University, Philadelphia, PA